Post-acute COVID-19 syndrome and kidney diseases: what do we know?
Post-acute COVID-19 syndrome and kidney diseases: what do we know?
复制标题
DOI：
10.1007/s40620-022-01296-y
复制
发表时间：
2022-04
影响因子：
3.4
通讯作者：
Kanbay M
中科院分区：
文献类型：
--
作者：
Copur S;Berkkan M;Basile C;Tuttle K;Kanbay M
COVID-19是一种由新型冠状病毒（SARS-CoV-2）引起的疾病，是一种主要的全球威胁，已演变为大流行病。尽管出现了多种疫苗接种替代方案并开发了治疗方案，但截至2021年11月，已记录了戏剧性的短期和长期临床结果，感染人数超过2.5亿，死亡人数超过500万。COVID-19在急性期表现出各种呼吸、心血管、神经精神、肌肉骨骼和肾脏特征;然而，最近强调了感染后阶段的肾脏受累。本综述旨在评估越来越多的关于SARS-CoV-2感染中肾脏受累的文献，沿着在感染急性期和急性后COVID-19期间报告的临床特征，评估解释此类情况的潜在病理生理学框架。慢性肾脏疾病和急性肾损伤（阿基）的发展，在最初的住院治疗过程中与高死亡率和发病率。此外，越来越多的证据表明，即使在急性期没有任何阿基体征的患者中，在6至12个月的随访期内肾功能也会下降。尽管存在这些问题，但没有指导方针规范此类患者人群的随访期或治疗替代方案。总之，COVID-19对肾脏的负担尚未确定。未来需要进行前瞻性大规模研究，并进行长期随访，通过多个参数评估肾脏受累，如活检研究、尿分析、血清肌酐和胱抑素C测量、直接测量肾小球滤过率以及通过尿β2-微球蛋白测量评估肾小管功能。
COVID-19, a disease caused by a novel coronavirus (SARS-CoV-2), is a major global threat that has turned into a pandemic. Despite the emergence of multiple vaccination alternatives and developing therapeutic options, dramatic short- and long-term clinical outcomes have been recorded with more than 250 million infected people and over 5 million deaths as of November 2021. COVID-19 presents various respiratory, cardiovascular, neuropsychiatric, musculoskeletal and kidney features during the acute phase; nevertheless, renal involvement in the post-infection period has recently been emphasized. The present review aims to evaluate the growing literature on kidney involvement in the SARS-CoV-2 infection along with clinical features reported both in the acute phase of the infection and in the post-acute COVID-19 period by assessing potential pathophysiological frameworks explaining such conditions. Chronic kidney disease and development of acute kidney injury (AKI) in the course of initial hospitalization are associated with high mortality and morbidity rates. Moreover, growing evidence suggests a decline in renal function in the 6-to-12-month follow-up period even in patients without any signs of AKI during the acute phase. Despite such concerns there are no guidelines regulating the follow-up period or therapeutic alternatives for such patient population. In conclusion, the burden of COVID-19 on the kidney is yet to be determined. Future prospective large scale studies are needed with long follow-up periods assessing kidney involvement via multiple parameters such as biopsy studies, urinalysis, measurement of serum creatinine and cystatin C, directly measured glomerular filtration rate, and assessment of tubular function via urinary β2-microglobulin measurements.
登录
查看更多内容
影响因子：
64.8
作者：
Al-Aly, Ziyad;Xie, Yan;Bowe, Benjamin
通讯作者：
Bowe, Benjamin
影响因子：
4.6
作者：
Carriazo S;Mas-Fontao S;Seghers C;Cano J;Goma E;Avello A;Ortiz A;Gonzalez-Parra E
通讯作者：
Gonzalez-Parra E
影响因子：
19.6
作者：
Cheng, Yichun;Luo, Ran;Xu, Gang
通讯作者：
Xu, Gang
影响因子：
13.6
作者：
Bowe, Benjamin;Xie, Yan;Al-Aly, Ziyad
通讯作者：
Al-Aly, Ziyad
影响因子：
5.4
作者：
Bosch, BJ;van der Zee, R;Rottier, PJM
通讯作者：
Rottier, PJM